US Cardiologists Release Updated Cholesterol Prevention Guidelines

On March 13, 2026, the American College of Cardiology and the American Heart Association — joined by nine other medical societies — released their first comprehensive update to cholesterol management guidelines since 2018 [1]. The 2026 Guideline on the Management of Dyslipidemia retires the previous framework and introduces stricter LDL cholesterol targets, a new risk calculator, expanded drug recommendations, and a push to begin treatment earlier in life [2]. An estimated one in four U.S. adults has elevated LDL cholesterol, placing millions squarely in the crosshairs of these changes [1].

The response has been swift and divided. Supporters see the update as a long-overdue alignment with accumulating trial evidence. Critics point to the writing committee's pharmaceutical industry ties, the high cost of newly recommended therapies, and questions about whether aggressive drug targets serve patients whose baseline risk is low.

What Changed: The New Targets

The most visible shift is the return of specific LDL cholesterol (LDL-C) numerical goals — something the 2018 guidelines deliberately avoided in favor of percentage-reduction targets [3].

For primary prevention (people without established cardiovascular disease), the 2026 guidelines introduce explicit LDL-C goals based on risk tier [2][4]:

• Borderline risk (3% to less than 5% ten-year risk): LDL-C below 100 mg/dL
• Intermediate risk (5% to less than 10%): LDL-C below 100 mg/dL
• High risk (10% or higher): LDL-C below 70 mg/dL

For secondary prevention (people with existing atherosclerotic cardiovascular disease, or ASCVD):

• Not at very high risk: LDL-C below 70 mg/dL
• Very high risk: LDL-C below 55 mg/dL — down from 70 mg/dL under the 2018 framework [4]

Source: ACC/AHA Guidelines (2018, 2026)

Data as of Mar 13, 2026CSV

The guidelines also expand attention beyond LDL-C alone. Non-HDL cholesterol targets now parallel LDL-C goals (generally 30 mg/dL higher). Apolipoprotein B (apoB) measurement — a blood test that counts atherogenic lipoprotein particles — is given a formal pathway for guiding treatment decisions for the first time in ACC/AHA guidelines [1][2]. Lipoprotein(a), or Lp(a) — a genetically determined lipid particle that raises cardiovascular risk independently of LDL — now carries a strong recommendation to be measured at least once in every adult's lifetime [1].

A New Risk Calculator

The 2026 guidelines adopt the PREVENT-ASCVD risk calculator, replacing the Pooled Cohort Equations (PCE) that had been in use since 2013 [5][6]. The old PCE was derived from roughly 25,000 individuals and had been shown to overestimate ten-year cardiovascular risk by 40% to 50% [5]. PREVENT, by contrast, was built from data on 6.5 million individuals and includes kidney function and metabolic health markers alongside traditional risk factors [1][6].

The new calculator is designed for adults aged 30 to 79 without known ASCVD, and it estimates both 10-year and 30-year risk of heart attack or stroke [5]. The longer time horizon matters: it shifts the conversation toward cumulative lifetime exposure to atherogenic lipoproteins, supporting the guidelines' emphasis on earlier intervention. Adults as young as 30 with LDL-C of 160 mg/dL or higher, or those with familial hypercholesterolemia, are now candidates for pharmacotherapy regardless of their short-term risk score [4].

A 2024 study reported by STAT News found that the PREVENT equations would reclassify roughly 4 million Americans who were previously recommended statins under the old PCE as no longer meeting the treatment threshold — suggesting that in some populations, the new calculator actually narrows the eligible pool [7]. However, the simultaneous introduction of absolute LDL-C targets and expanded age ranges likely offsets that reduction, though precise population-level estimates have not yet been published.

The Drug Recommendations: Beyond Statins

Statins remain the foundation of therapy. But the 2026 guidelines expand the role of several newer drug classes when statins alone do not achieve LDL-C goals [2][4]:

Ezetimibe — an oral cholesterol-absorption inhibitor now available as a generic — is recommended as the first add-on therapy. At roughly $25 per month without insurance, it is the most affordable non-statin option [8].

Bempedoic acid (brand name Nexletol) — an oral ACL inhibitor that blocks cholesterol synthesis upstream of the pathway where statins act — received stronger endorsement than in previous guidance. The CLEAR Outcomes trial, published in the New England Journal of Medicine in 2023, showed a 13% relative reduction in major adverse cardiovascular events among statin-intolerant patients [9]. That trial enrolled nearly 14,000 patients and was funded by Esperion Therapeutics, bempedoic acid's manufacturer [9]. Without insurance, bempedoic acid costs approximately $450 per month [10].

PCSK9 inhibitors — evolocumab (Repatha) and alirocumab (Praluent) — are injectable monoclonal antibodies that reduce LDL-C by 45% to 60% on top of statin therapy [11]. They are recommended for patients who cannot reach LDL-C targets with statins and ezetimibe. The VESALIUS-CV trial of evolocumab, which demonstrated reductions in coronary heart disease death, myocardial infarction, and stroke in patients achieving LDL-C levels as low as 45 mg/dL, was considered by the committee before its publication — a fact that has drawn scrutiny [4]. Without insurance, Repatha carries a list price of $573 per month, and Praluent approximately $630 per month, though Amgen's direct-to-patient program offers Repatha at $239 per month for eligible cash-paying patients [10][12].

Inclisiran (Leqvio) — a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 — requires only twice-yearly injections after initial dosing. Phase III trials showed LDL-C reductions of approximately 50% [11]. Each dose is priced above $3,000, though long-term cardiovascular outcomes data are still pending [11][4]. The guidelines note inclisiran may be considered when patients cannot tolerate or adhere to PCSK9 monoclonal antibodies.

Source: Drug pricing sources (2026)

Data as of Mar 1, 2026CSV

Starting in 2026, Medicare Part D's out-of-pocket cap of $2,100 per year will help some patients afford these drugs [12]. But for uninsured or underinsured Americans — and for those on high-deductible commercial plans — the cost barrier remains substantial. Most insurers require prior authorization and step therapy, meaning patients must first try and fail cheaper alternatives before gaining access to PCSK9 inhibitors or inclisiran [12].

Who Pays, and Who Benefits: The Equity Question

An estimated 92 million American adults — roughly 35% of the adult population — report taking a statin [7]. The demographic distribution of both statin eligibility and access is uneven. A 2024 analysis documented significant disparities in guideline-recommended statin use by race, ethnicity, and sex, with Black and Hispanic adults less likely to receive recommended therapy despite bearing a disproportionate burden of cardiovascular disease [13].

The 2026 guidelines acknowledge this gap. They list "higher-risk ancestry (e.g., South Asian and Filipino)" as a risk-enhancing factor and include management considerations based on race and ethnicity [4]. Yet the guidelines do not address the structural barriers — cost, insurance coverage, primary care access — that drive the disparity. Patients in the populations most likely to benefit from aggressive lipid management are also those most likely to face obstacles to filling a prescription.

For South Asian Americans, who have two to four times the prevalence of premature coronary artery disease compared to the general population, the explicit recognition of ancestry-based risk is a meaningful step. Whether it translates into better outcomes depends on whether the healthcare system can deliver the recommended treatments to those patients.

The Conflict-of-Interest Question

The 2018 cholesterol guideline committee was notable for having all members free of recent and relevant industry conflicts [14]. The 2026 committee marked a sharp departure from that standard.

Of the 33 writing committee members, approximately half — about 16 — disclosed relevant financial relationships with pharmaceutical manufacturers, imaging companies, digital health firms, or genetic testing companies [15]. Several members held relationships spanning what one critic described as "the entire landscape of novel lipid-lowering agents that this guideline governs" [15]. The peer review committee was even more entangled: over two-thirds of its 29 members disclosed relevant industry conflicts [15].

Dr. James Stein, a cardiologist at the University of Wisconsin who has served on data safety monitoring boards for Lilly, Novartis, and Silence Therapeutics, published a detailed critique of the committee's composition. He argued that "disclosure is not the same as management" and that the ACC/AHA's conflict-of-interest framework "produces guidelines written by people with substantial financial stakes in the recommendations those guidelines contain" [15]. Stein further noted that intellectual biases from deep professional investment in a field — biases not captured in any disclosure table — may be amplified by a "licensing effect," where the act of transparent disclosure makes advisors more willing to give biased advice [15].

The Institute of Medicine (now the National Academy of Medicine) recommended in a 2009 report that clinical guideline panels be chaired by individuals without conflicts and that a majority of members be conflict-free. The 2026 ACC/AHA guideline does not appear to meet that standard, though the ACC/AHA's November 2025 methodology manual describes its own conflict management process [14][16].

The Evidence Base: Strong, but Not Uniform

The clinical trial literature supporting lower LDL-C targets has grown substantially since 2018. More than 17,600 papers on PCSK9 inhibitors and cardiovascular outcomes have been published, with annual output peaking at 2,808 in 2025 [17].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Key trials informing the 2026 guidelines include:

• CLEAR Outcomes (2023): Bempedoic acid reduced major cardiovascular events by 13% in statin-intolerant patients. Funded by Esperion Therapeutics. The trial was completed as planned, not stopped early [9].
• VESALIUS-CV: Evolocumab in primary prevention patients with subclinical atherosclerosis showed reductions in coronary events at LDL-C levels of 45 mg/dL [4].
• FOURIER and ODYSSEY Outcomes (earlier trials): Established the cardiovascular benefit of PCSK9 inhibitors in secondary prevention.

However, the evidence quality behind individual recommendations varies. Dr. Stein's analysis found that only about 20% of the guideline's roughly 70 Class 1 ("is recommended") pronouncements rest on Level A evidence — meaning they are supported by multiple randomized controlled trials or meta-analyses [15]. Approximately 40% rest on Level B-NR evidence, drawn from observational or nonrandomized data. "Nearly half of all 'is recommended' pronouncements lack any RCT evidence base," Stein wrote [15].

The guidelines' Class 1 recommendation for coronary artery calcium (CAC) scoring — a CT scan that quantifies plaque in the heart's arteries — was specifically challenged. No randomized trial has demonstrated that a CAC-driven treatment strategy reduces downstream cardiovascular events, yet the guideline converts prognostic associations from cohort studies into treatment-initiation algorithms [15]. Similarly, the recommendation for genetic testing in "possible" familial hypercholesterolemia drew criticism for relying on a diagnostic yield of only 2% to 5% [15].

The Case Against Aggressive Pharmacological Targets

The strongest objections to expanding drug-based cholesterol management come not from fringe skeptics but from within mainstream cardiology and evidence-based medicine.

Dr. Rita Redberg, a cardiologist at the University of California, San Francisco, and former editor of JAMA Internal Medicine, has argued for years that the focus on cholesterol as a treatment target — rather than on overall cardiovascular health — drives overprescription [18]. She and co-authors have published analyses showing that in patients without preexisting cardiovascular disease, statins offer modest absolute risk reductions. In one frequently cited framing: for every 1,000 low-risk individuals treated with statins for one year, roughly 13 will benefit — meaning 987 take the drug without measurable personal gain [19].

The Cochrane Collaboration's reviews of statins in primary prevention have found that while statins reduce cardiovascular events in relative terms, the absolute benefit in low-to-moderate-risk populations is small [19]. Critics argue that relative risk reduction — the metric most commonly emphasized in trial publications and guidelines — obscures this reality. A 25% relative risk reduction sounds large; a 1% absolute risk reduction, which may describe the same data, sounds appropriately modest.

Writing in JAMA Internal Medicine in 2022, Dr. Redberg and colleague Dr. Rita Rubin argued that "it is time to curb our enthusiasm" for statins in primary prevention, pointing to the gap between relative and absolute benefit and the underweighting of statin side effects — including muscle symptoms that affect an estimated 5% to 20% of users [18].

Defenders of the guidelines counter that population-level thinking requires different math. If tens of millions of people take statins, even small per-person absolute risk reductions translate into hundreds of thousands of prevented heart attacks and strokes over a decade. They also note that newer evidence supports lower LDL-C targets as safe, with no identified floor below which further reduction causes harm [2].

How the US Compares to Europe

The 2025 European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) focused update, released months before the US guidelines, arrived at broadly similar targets: LDL-C below 55 mg/dL for very-high-risk patients and below 70 mg/dL for high-risk patients, with a 50% or greater reduction from baseline [20][21]. The ESC guidelines have endorsed these aggressive targets since 2019 and have been more willing than US guidelines to recommend combination therapy — adding ezetimibe, PCSK9 inhibitors, or bempedoic acid — to reach goals [20].

In European countries that adopted these targets early, observational data suggest improved cardiovascular outcomes, though isolating the effect of guideline changes from broader trends in care is difficult. The ESC/EAS update also gave bempedoic acid its strongest endorsement yet, recommending it for patients unable to take statins and as an add-on for those not reaching goals on maximally tolerated doses [21].

One persistent concern across both systems: the rate of statin-associated muscle symptoms. European registries report that 7% to 29% of statin users experience muscle complaints, though placebo-controlled trials consistently show much smaller differences between statin and placebo arms — a discrepancy attributed partly to the "nocebo effect," where patient expectations of side effects produce real symptoms [20].

The 10-Year Horizon

Precise projections for the US healthcare system under the new guidelines have not been published. But the broad strokes are predictable.

With roughly 92 million Americans already taking statins and one in four adults carrying elevated LDL-C, the expanded target population — especially the push to treat younger adults with LDL-C above 160 mg/dL and the new borderline-risk category — could add millions of new statin users over the next decade [1][7]. The downstream demand for non-statin add-ons will grow in proportion: every patient who does not reach their newly defined LDL-C target on statins alone becomes a candidate for ezetimibe, bempedoic acid, or a PCSK9 inhibitor.

Medicare and Medicaid spending on lipid-lowering drugs will almost certainly rise, though the 2026 Medicare Part D out-of-pocket cap softens the per-patient impact [12]. The degree to which these costs are offset by reduced hospitalizations for heart attacks and strokes — where a single event can cost $50,000 to $200,000 — will depend on adoption rates, patient adherence, and how many of the newly treated individuals were at genuinely elevated risk.

The tension at the center of these guidelines is not whether lower LDL-C reduces cardiovascular events in high-risk patients. The evidence there is substantial. The tension is about the margins: how far down the risk spectrum to push pharmacotherapy, how much the healthcare system should spend to do so, and whether the committee that made those decisions was positioned to weigh the tradeoffs without bias.

The 2026 dyslipidemia guidelines represent the most aggressive cholesterol-management framework in ACC/AHA history. Whether they represent the right balance between ambition and restraint will be argued for years — in clinics, in formulary meetings, and in the medical literature that will inevitably follow.